BR112018076593A2 - 99mtc-edda/hynic-ipsma como um radiofármaco para a detecção da superexpressão do antigeno prostático de membrana - Google Patents
99mtc-edda/hynic-ipsma como um radiofármaco para a detecção da superexpressão do antigeno prostático de membranaInfo
- Publication number
- BR112018076593A2 BR112018076593A2 BR112018076593-7A BR112018076593A BR112018076593A2 BR 112018076593 A2 BR112018076593 A2 BR 112018076593A2 BR 112018076593 A BR112018076593 A BR 112018076593A BR 112018076593 A2 BR112018076593 A2 BR 112018076593A2
- Authority
- BR
- Brazil
- Prior art keywords
- radiopharmaceutical
- hynic
- ipsma
- edda
- 99mtc
- Prior art date
Links
- 239000012217 radiopharmaceutical Substances 0.000 title abstract 5
- 229940121896 radiopharmaceutical Drugs 0.000 title abstract 5
- 230000002799 radiopharmaceutical effect Effects 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 title abstract 2
- 239000012528 membrane Substances 0.000 title abstract 2
- 230000002018 overexpression Effects 0.000 title abstract 2
- 210000002307 prostate Anatomy 0.000 title abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- KOUZWQLNUJWNIA-UHFFFAOYSA-N 2-hydrazinylpyridine-3-carboxamide Chemical compound NNC1=NC=CC=C1C(N)=O KOUZWQLNUJWNIA-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 125000003636 chemical group Chemical group 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000009206 nuclear medicine Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
a presente invenção refere-se a um novo radiofármaco inibidor do antígeno prostático especifico de membrana (ipsma) que contém hidrazinonicotinamida (hynic) como um grupo químico crítico no incremento da lipofilia da molécula para o acoplamento aos sítios hidrófobos do psma, unido ao uso convencional de hynic como um agente de quelação para o radiometal 99mtc, onde o ácido etilenodiaminodiacético (edda) é usado para completar a esfera de coordenação do radiometal. o novo radiofármaco de 99mtc-edda/hynic-ipsma detecta, com alta afinidade e sensibilidade in vivo, a proteína psma superexpressa em células de câncer de próstata por meio de técnicas de imagem molecular spect em medicina nuclear. o objetivo da presente invenção consiste na provisão de um novo radiofármaco específico (radiofármaco de alvos moleculares) do spect com alta sensibilidade para a detecção de tumores com superexpressão de psma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXMX/A/2016/008466 | 2016-06-24 | ||
| MX2016008466A MX2016008466A (es) | 2016-06-24 | 2016-06-24 | 99mtc-edda/hynic-ipsma como un radiofarmaco para la deteccion de la sobre-expresion del antigeno prostatico de membrana. |
| PCT/MX2017/000068 WO2017222362A1 (es) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma como un radiofármaco para la detección de la sobre-expresión del antigeno prostático de membrana |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018076593A2 true BR112018076593A2 (pt) | 2019-04-16 |
| BR112018076593B1 BR112018076593B1 (pt) | 2022-05-24 |
Family
ID=60783979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018076593-7A BR112018076593B1 (pt) | 2016-06-24 | 2017-06-21 | Composto para radiomarcação, composto radiofarmacêutica, e composição radiofarmacêutica |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10918745B2 (pt) |
| EP (2) | EP4083049A3 (pt) |
| CN (1) | CN109641924B (pt) |
| BR (1) | BR112018076593B1 (pt) |
| CA (1) | CA3059545C (pt) |
| DK (1) | DK3486249T3 (pt) |
| EA (1) | EA201892668A1 (pt) |
| ES (1) | ES2906332T3 (pt) |
| HU (1) | HUE057891T2 (pt) |
| MA (1) | MA45687A (pt) |
| MX (1) | MX2016008466A (pt) |
| PL (1) | PL3486249T3 (pt) |
| PT (1) | PT3486249T (pt) |
| WO (1) | WO2017222362A1 (pt) |
| ZA (1) | ZA201807828B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018003175A (es) | 2018-03-14 | 2019-09-16 | Instituto Nac De Investigaciones Nucleares | 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana. |
| PL239934B1 (pl) | 2019-04-12 | 2022-01-31 | Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom | Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty |
| CN111233758B (zh) * | 2020-03-02 | 2021-04-23 | 北京大学第一医院 | 一种psma抑制剂及其应用和靶向psma的核素成像试剂 |
| CN111253465A (zh) * | 2020-03-03 | 2020-06-09 | 复旦大学附属肿瘤医院 | 一种psma结合剂及其用途 |
| US20230097381A1 (en) * | 2020-04-24 | 2023-03-30 | Radiomedix, Inc. | Composition, kit and method for diagnosis and treatment of prostate cancer |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| CA3217589A1 (en) | 2021-05-31 | 2022-12-08 | Frederik Giesel | Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof |
| WO2023030509A1 (zh) * | 2021-09-03 | 2023-03-09 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| CN114569744A (zh) * | 2022-03-08 | 2022-06-03 | 安徽淮仁堂药业股份有限公司 | 一种锝前列腺标特异性膜抗原显像剂试剂盒及其制备方法和应用 |
| CN115260155B (zh) * | 2022-08-08 | 2023-11-10 | 北京师范大学 | 一种含三唑环和肼基尼古酰胺基的谷氨酸-脲衍生物及其应用 |
| CN117434270B (zh) * | 2023-09-11 | 2024-05-07 | 江苏省人民医院（南京医科大学第一附属医院） | 一种可携带放射性信号的蛋白质支架及其抗体检测中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3466928A1 (en) | 2007-06-26 | 2019-04-10 | The Johns Hopkins University | Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| MX336322B (es) * | 2010-04-08 | 2016-01-12 | Inst Nac De Investigaciones Nucleares | 99mtc-edda/hynic-ggc-aunp-manosa como un nuevo radiofarmaco para la deteccion del ganglio centinela en cancer de mama. |
| CN102949735B (zh) | 2011-08-30 | 2015-06-10 | 北京大基康明医疗设备有限公司 | 放射性药物的制备方法及系统 |
| CN109125745B (zh) | 2012-04-10 | 2022-07-26 | 蓝瑟斯医学影像公司 | 放射性药物合成方法 |
| WO2016062370A1 (en) * | 2014-10-20 | 2016-04-28 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
-
2016
- 2016-06-24 MX MX2016008466A patent/MX2016008466A/es unknown
-
2017
- 2017-06-21 DK DK17815772.3T patent/DK3486249T3/da active
- 2017-06-21 ES ES17815772T patent/ES2906332T3/es active Active
- 2017-06-21 MA MA045687A patent/MA45687A/fr unknown
- 2017-06-21 PL PL17815772T patent/PL3486249T3/pl unknown
- 2017-06-21 EA EA201892668A patent/EA201892668A1/ru unknown
- 2017-06-21 EP EP21205156.9A patent/EP4083049A3/en active Pending
- 2017-06-21 WO PCT/MX2017/000068 patent/WO2017222362A1/es unknown
- 2017-06-21 CA CA3059545A patent/CA3059545C/en active Active
- 2017-06-21 CN CN201780049494.4A patent/CN109641924B/zh active Active
- 2017-06-21 HU HUE17815772A patent/HUE057891T2/hu unknown
- 2017-06-21 EP EP17815772.3A patent/EP3486249B1/en active Active
- 2017-06-21 PT PT178157723T patent/PT3486249T/pt unknown
- 2017-06-21 BR BR112018076593-7A patent/BR112018076593B1/pt active IP Right Grant
- 2017-06-21 US US16/310,744 patent/US10918745B2/en active Active
-
2018
- 2018-11-20 ZA ZA2018/07828A patent/ZA201807828B/en unknown
-
2020
- 2020-12-28 US US17/135,424 patent/US11547767B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190343970A1 (en) | 2019-11-14 |
| CA3059545C (en) | 2021-07-27 |
| WO2017222362A1 (es) | 2017-12-28 |
| EA201892668A1 (ru) | 2019-10-31 |
| EP3486249A1 (en) | 2019-05-22 |
| BR112018076593B1 (pt) | 2022-05-24 |
| EP3486249B1 (en) | 2021-11-10 |
| CA3059545A1 (en) | 2017-12-28 |
| US11547767B2 (en) | 2023-01-10 |
| DK3486249T3 (da) | 2022-02-07 |
| HUE057891T2 (hu) | 2022-06-28 |
| ES2906332T3 (es) | 2022-04-18 |
| PT3486249T (pt) | 2022-02-02 |
| MX2016008466A (es) | 2017-12-25 |
| US20210187132A1 (en) | 2021-06-24 |
| EP4083049A2 (en) | 2022-11-02 |
| PL3486249T3 (pl) | 2022-05-23 |
| EP3486249A4 (en) | 2020-03-11 |
| CN109641924B (zh) | 2022-02-25 |
| US10918745B2 (en) | 2021-02-16 |
| EP4083049A3 (en) | 2022-12-21 |
| MA45687A (fr) | 2021-03-31 |
| ZA201807828B (en) | 2021-03-31 |
| CN109641924A (zh) | 2019-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018076593A2 (pt) | 99mtc-edda/hynic-ipsma como um radiofármaco para a detecção da superexpressão do antigeno prostático de membrana | |
| Nouri et al. | Identification of celastrol as a novel YAP-TEAD inhibitor for cancer therapy by high throughput screening with ultrasensitive YAP/TAZ–TEAD biosensors | |
| BR112012013915A8 (pt) | anticorpos anti-c4. 4a e usos dos mesmos | |
| BR112016004320A2 (pt) | biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste | |
| MX2015000684A (es) | Metodo para detectar cancer. | |
| MX2015000686A (es) | Metodo para detectar cancer. | |
| BR112016009460A8 (pt) | método para detectar a presença de anticorpos neutralizantes, e, kit | |
| Dixit et al. | Synthesis of clinical-grade [18F]-fluoroestradiol as a surrogate PET biomarker for the evaluation of estrogen receptor-targeting therapeutic drug | |
| Inomata et al. | Downregulation of miR-122-5p activates glycolysis via PKM2 in Kupffer cells of rat and mouse models of non-alcoholic steatohepatitis | |
| Summer et al. | Pretargeted imaging with Gallium-68—improving the binding capability by increasing the number of tetrazine motifs | |
| Wang et al. | Broadly reactive IgG responses to heterologous H5 prime-boost influenza vaccination are shaped by antigenic relatedness to priming strains | |
| Asar et al. | Phage display selection, identification, and characterization of novel pancreatic cancer targeting peptides | |
| MX2010011900A (es) | Método de cuantificación de aminoácidos por cromatografía líquida de alta resolución (hplc) a partir de una fermentación láctica. | |
| Chernov et al. | Phase I trial of [99mTc] Tc-maSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors | |
| Grashei et al. | Conversion of hyperpolarized [1-13c] pyruvate in breast cancer cells depends on their malignancy, metabolic program and nutrient microenvironment | |
| Sampadi et al. | Phosphoproteomics sample preparation impacts biological interpretation of phosphorylation signaling outcomes | |
| Basuli et al. | Fluorine-18 labeled fluorofuranylnorprogesterone ([18F] FFNP) and dihydrotestosterone ([18F] FDHT) prepared by “Fluorination on Sep-Pak” method | |
| Csikos et al. | In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn] Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model | |
| Liu et al. | Quantitative analysis of histone H3 and H4 post‐translational modifications in doxorubicin‐resistant leukemia cells | |
| Raghavan et al. | A” Clickable” Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT | |
| Jiang et al. | Development and evaluation of a peptide heterodimeric tracer targeting CXCR4 and integrin αvβ3 for pancreatic cancer imaging | |
| WO2012149552A3 (en) | Dual-isotope positron emitting tomography for disease evaluation | |
| Gündel et al. | Quantitation of the A2A Adenosine Receptor Density in the Striatum of Mice and Pigs with [18F] FLUDA by Positron Emission Tomography | |
| Eder et al. | A new class of PSMA-617-based hybrid molecules for preoperative imaging and intraoperative fluorescence navigation of prostate cancer | |
| Wang et al. | Noninvasive mapping of angiotensin converting enzyme-2 in pigeons using micro positron emission tomography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/06/2017, OBSERVADAS AS CONDICOES LEGAIS |